Related Experiment Video
Updated: Jul 19, 2026
12:34
Two-dimensional Gel Electrophoresis Coupled with Mass Spectrometry Methods for an Analysis of Human Pituitary Adenoma Tissue Proteome
Published on: April 2, 2018
[IGF-1 plasma levels evaluation in prolactinoma].
Daniela Zylberberg1, Erika C O Naliato, Alair Sarmet
1Hospital Universitario Clementino Fraga Filho, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil.
Arquivos De Neuro-Psiquiatria
|October 24, 2006
Summary
Prolactinoma patients may have co-secreting growth hormone (GH). Initial evaluation of elevated insulin-like growth factor-1 (IGF-1) in prolactinoma is recommended to detect mixed GH/PRL tumors, though acromegaly criteria were not met.
Area of Science:
- Endocrinology
- Oncology
- Pituitary Disorders
Context:
- Prolactinomas are the most common pituitary tumors.
- Co-secretion of growth hormone (GH) can occur.
- Insulin-like growth factor-1 (IGF-1) is a key marker for GH activity and acromegaly diagnosis.
Purpose:
- To investigate the prevalence of mixed GH and prolactin (PRL) secreting tumors in prolactinoma patients.
- To assess the utility of initial IGF-1 level analysis in identifying these mixed tumors.
Summary:
- A study evaluated 34 prolactinoma patients (7 men, 27 women) aged 19-72.
- Elevated basal GH (>0.4 ng/mL) and IGF-1 levels were observed more frequently than expected.
- However, no patients met the diagnostic criteria for acromegaly after glucose tolerance testing (GTT).
Impact:
- Suggests routine IGF-1 evaluation for prolactinoma patients due to the risk of GH co-secretion.
- Highlights the need for vigilance regarding patients with decreasing PRL levels without tumor shrinkage.